Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Biomedtracker: see the drug development process through analysts’ eyes

Real-time tracking and analysis of the drug development pipeline

Key benefits:

Market Events & Catalysts
Likelihood of Approval
Deals Coverage

Strategic Transactions is now part of Biomedtracker

Strategic Transactions, the pioneer in deals intelligence, has been integrated into a more powerful commercial strategy solution.

Key benefits:

Looking for a needle in a haystack opportunity?
Trying to predict the future of drug approvability and commercial success?
In search of company and deals intelligence to evaluate potential partnerships?

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

View all content

Biomedtracker, Meddevicetracker

Q4 Outlook Report 2020

The world-class data contained in this report extract will keep you up to speed on the drug development landscape for better decision-making

View article
Scrip

Quick Listen: Scrip's Five Must-Know Things

Take a brief audio tour around the main biopharma industry events of the past week, as brought to you by Scrip's global team, in this podcast version of Five Must-Know Things.

Topic Coronavirus M A

Full podcast
Scrip

Novartis's Canakinumab Fails In COVID-19 Pneumonia Patients

Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.

Topic Coronavirus Clinical Trials

View article
Scrip

Pfizer And BioNTech Claim COVID19 Vaccine Success

The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.

Topic Coronavirus BioPharmaceutical

View article
Generics Bulletin

Pfizer Reports 80% Biosimilars Growth In Q3

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals

View article
HBW Insight

Sanofi's New Consumer Chief Identifies 'Untapped Potential' In Digital

Sanofi's recently-appointed Consumer Healthcare head Julie Van Ongevalle says she has identified "untapped potential" for the business to utilize "cutting edge digital platforms." Van Ongevalle revealed her early plans for Sanofi as it reported a drop in Q3 sales.

Topic Sales Earnings Digital Health

View article
Scrip

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Topic Sales Earnings

Full podcast
Scrip

Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

Topic Coronavirus Sales Earnings Business Strategies

View article
Scrip

Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags

Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.

Topic Coronavirus Vaccines Sales Earnings

View article
Scrip

Scrip Asia 100 Report Extract

In a year epitomized by a global pandemic, the depth and implications of pharma activity across Asia has been staggering. Gain unique insight into the companies, products and themes leading the industry when you download the Scrip Asia 100 Report, written by our experienced on-the-ground journalists throughout this vast region.

Topic Business Strategies

Single report
HBW Insight

COVID-19 Concerns Could Enhance Ongoing Bloom Of Plant Based Sports Nutrition Sales

"One of the issues that COVID-19 has brought out is, how safe is the production of animal-based food products?" says Innova Market Insights North America executive Tom Vierhile at AHPA sports nutrition conference.

Topic Coronavirus Dietary Supplements Market Intelligence

View article
Scrip

Quick Listen: Scrip's Five Must-Know Things

Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team

Topic Coronavirus Research & Development

Full podcast
Scrip

Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results

Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air

Topic Sales Earnings Coronavirus

View article
Scrip

Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks

The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up

Topic Vaccines Coronavirus

View article
Scrip, Datamonitor Healthcare

Top 10 Best-Selling Drugs of 2019

In 2019, the 10 most lucrative medicines generated combined global sales of $92.5B. Scrip provides insight into these top sellers and the companies behind them, as well US dynamics, global sales forecasts and lifecycle data, with complementary market analysis from Datamonitor Healthcare on diseases targeted, indications, and more.

Topic Drug Review Diseases

Single report